VENCLEXTA is a prescription medicine used in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with
newly diagnosed acute myeloid leukemia (AML) who are 75 years of age or older, or who have other medical conditions that prevent the use of standard chemotherapy. It is not known if VENCLEXTA is safe and effective in children.

VENCLEXTA + azacitidine

Proven to help some
adults with
diagnosed AML live longer

Actor portrayal.

Half of patients treated with VENCLEXTA + azacitidine were still alive at 15 months vs 10 months for those receiving treatment with azacitidine alone.

In a clinical study of 431 adults with newly diagnosed AML, who were 75 years of
age or older, or who had other medical conditions that prevented the use of
standard chemotherapy, 286 patients received VENCLEXTA + azacitidine and
145 patients received azacitidine + placebo (an inactive medication), also
considered as azacitidine alone.

Actor portrayal.

Have questions about your treatment with VENCLEXTA?

Call our nurse support line for VENCLEXTA.

You can speak with our Registered Nurses about your treatment with VENCLEXTA—at no cost to you.

Call our nurse support line:
Monday–Friday, 7am–7pm CST

Call our nurse support line:

Monday-Friday, 7am – 7pm CST

The nurses from the nurse support line are provided by AbbVie and do not work under the direction of a healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.